Wolfe Research initiated coverage on Exelixis
$EXEL
Biotechnology: Biological Products (No Diagnostic Substances)
Health Care
Wolfe Research initiated coverage of Exelixis with a rating of Peer Perform
Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 1/8/2026 | $48.00 | Overweight → Equal-Weight | Morgan Stanley |
| 1/5/2026 | $41.00 | Neutral → Underperform | BofA Securities |
| 11/18/2025 | Peer Perform | Wolfe Research | |
| 11/3/2025 | Buy → Neutral | Guggenheim | |
| 10/21/2025 | $48.00 | Market Perform → Outperform | Leerink Partners |
| 9/19/2025 | $40.00 | Equal Weight | Barclays |
| 9/17/2025 | $40.00 | Equal Weight | Barclays |
| 9/17/2025 | $47.00 | Buy | Goldman |
8-K - EXELIXIS, INC. (0000939767) (Filer)
10-Q - EXELIXIS, INC. (0000939767) (Filer)
8-K - EXELIXIS, INC. (0000939767) (Filer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
4 - EXELIXIS, INC. (0000939767) (Issuer)
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-16) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/20/2023. Application Category: NDA, Application Number: 208692, Application Classification: Labeling
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-14) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 07/14/2022. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Submission status for EXELIXIS INC's drug CABOMETYX (SUPPL-12) with active ingredient CABOZANTINIB S-MALATE has changed to 'Approval' on 09/17/2021. Application Category: NDA, Application Number: 208692, Application Classification: Efficacy
Morgan Stanley downgraded Exelixis from Overweight to Equal-Weight and set a new price target of $48.00
BofA Securities downgraded Exelixis from Neutral to Underperform and set a new price target of $41.00
Wolfe Research initiated coverage of Exelixis with a rating of Peer Perform
– STELLAR-316 will use Natera's Signatera™ assay to identify MRD-positive patients for trial enrollment and to monitor response to therapy – Exelixis, Inc. (NASDAQ:EXEL) and Natera (NASDAQ:NTRA), a global leader in cell-free DNA and precision medicine, today announced their collaboration on the planned Exelixis-sponsored STELLAR-316 trial. This randomized phase 3 pivotal trial will evaluate zanzalintinib, Exelixis' novel oral kinase inhibitor, with and without an immune checkpoint inhibitor, in patients with resected stage II/III colorectal cancer (CRC). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260107329077/en/ Using Nat
– Presentation to be webcast on www.exelixis.com – Exelixis, Inc. (NASDAQ:EXEL) today announced that Michael M. Morrissey, Ph.D., the company's President and Chief Executive Officer, will provide a corporate overview at the J.P. Morgan 2026 Healthcare Conference on Monday, January 12, 2026 at 5:15 p.m. PT / 8:15 p.m. ET. To access the webcast link, log onto www.exelixis.com and proceed to the Event Calendar page under the Investors & News heading. A replay will also be available at the same location for at least 30 days. About Exelixis Exelixis is a globally ambitious oncology company innovating next-generation medicines and regimens at the forefront of cancer care. Powered by drug
VANCOUVER, British Columbia, Dec. 12, 2025 (GLOBE NEWSWIRE) -- Equity-Insider.com News Commentary – The FDA approved the first perioperative immunotherapy for early gastric and gastroesophageal junction cancers last month, ushering in a new clinical paradigm for patients with historically resistant tumors [1]. Separately, the agency fast-tracked an experimental pancreatic cancer therapy based on early trial results showing tumors shrinking in nearly a third of patients[2]. These regulatory milestones position immunotherapy platforms capable of unlocking durable responses across multiple gastrointestinal malignancies as the next wave of commercial opportunity, drawing attention to developer
- Total Revenues of $597.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $542.9 million - - GAAP Diluted EPS of $0.69, Non-GAAP Diluted EPS of $0.78 - - Announced Additional Stock Repurchase Program for up to $750 million by the End of 2026 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the third quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "In the third quarter of 2025, Exelixis gained momentum in the cabozantinib franchise and delivered on critical strategic priorities
– Conference Call and Webcast to Follow at 5:00 p.m. ET / 2:00 p.m. PT – Exelixis, Inc. (NASDAQ:EXEL) announced today that its third quarter 2025 financial results will be released on Tuesday, November 4, 2025 after the markets close. At 5:00 p.m. ET / 2:00 p.m. PT, Exelixis management will host a conference call and webcast to discuss the results and provide a general business update. Access to the event is available via the Internet from the company's website. To access the conference call, please register using this link. Upon registration, a dial-in number and unique PIN will be provided to join the call. To access the live webcast link, log onto www.exelixis.com and proceed to the
- Total Revenues of $568.3 million, Cabozantinib Franchise U.S. Net Product Revenues of $520.0 million - - GAAP Diluted EPS of $0.65, Non-GAAP Diluted EPS of $0.75 - - Conference Call and Webcast Today at 5:00 PM Eastern Time - Exelixis, Inc. (NASDAQ:EXEL) today reported financial results for the second quarter of 2025, provided an update on progress toward achieving key corporate objectives, and outlined its commercial, clinical and pipeline development milestones. "Exelixis continued to execute on our corporate objectives in the second quarter of 2025, delivering on key commercial, development and pipeline milestones," said Michael M. Morrissey, Ph.D., President and Chief Executiv
DIAMOND BAR, Calif., Oct. 21, 2025 /PRNewswire/ -- The Institute for Follicular Lymphoma Innovation (IFLI), a global, non-profit, private foundation dedicated to accelerating the development of innovative treatment options for patients with follicular lymphoma (FL)., today announced the appointments of Mehrdad Mobasher, M.D., M.P.H., and Carol O'Hear, M.D., Ph.D., as Executive Partners. "I believe Carol and Mehrdad will be exceptional partners to the IFLI team and portfolio as they bring decades of strategic leadership and drug development expertise," said David McCullagh, Man
– Dr. Aftab has served for over 25 years at Exelixis and has been instrumental in driving the company's scientific innovation and development activities – Exelixis, Inc. (NASDAQ:EXEL) today announced it has appointed Dana T. Aftab, Ph.D., as its Executive Vice President, Research and Development. In this new role, Dr. Aftab will oversee all aspects of the company's drug discovery, translational research, product development and medical affairs activities. "Dana has been an integral part of the Exelixis team for more than 25 years, with deep expertise that spans the drug discovery and development continuum. He's been a key contributor to many of Exelixis' most important milestones, inclu
Equity Insider News CommentaryIssued on behalf of Oncolytics Biotech Inc. VANCOUVER, BC, July 8, 2025 /PRNewswire/ -- Equity Insider News Commentary – As cancer rates climb and drug costs continue to soar, pressure is mounting on the private sector to drive innovation. Now, cancer experts are alarmed over a "gut wrenching" plan from the U.S. government to cut nearly 40% of National Cancer Institute funding, even as the price of oncology treatments pushes new limits—raising urgent concerns about access and affordability. In this shifting landscape, investors are turning their attention to a new wave of biotechs and specialty care providers developing breakthrough therapies and smarter care mo
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)
SC 13G - EXELIXIS, INC. (0000939767) (Subject)
SC 13D/A - EXELIXIS, INC. (0000939767) (Subject)